SCHEMBL5534065

SCHEMBL5534065

C#Cc1ccc(NC(=O)c2cc(Cl)ccc2N(C=O)c2ccc(C=NN(C)CCN(C)C)cc2F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 6/20 0.41
F2 P00734 3/20 0.34
P2RX1 P51575 3/20 0.34
TMPRSS4 Q9NRS4 1/20 0.33
NPC1 O15118 3/20 0.33
KMT2A Q03164 3/20 0.33
RAB9A P51151 2/20 0.33
POLB P06746 1/20 0.33
AHR P35869 1/20 0.33
MEN1 O00255 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
ACHE P22303 1/20 0.32
MAOB P27338 1/20 0.32
ALDH1A1 P00352 2/20 0.31
GAA P10253 2/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538435 0.95 F10 (0.40) F10F2P2RX1TMPRSS4NPC1
SCHEMBL5533806 0.94 F10 (0.33) F10F2
SCHEMBL5534354 0.90 F10 (0.44) F10P2RX1TMPRSS4NPC1KMT2A
SCHEMBL5538464 0.90 F10 (0.42) F10F2P2RX1TMPRSS4NPC1
SCHEMBL5535973 0.89 LCK (0.33) F10
SCHEMBL5539465 0.88 NPC1 (0.34) F10NPC1KMT2ARAB9APOLB
SCHEMBL5533499 0.86 F10 (0.38) F10NPC1RAB9ATDP1HTT
SCHEMBL5535752 0.86 F10 (0.32) F10HTT
SCHEMBL5532034 0.85 KDM4E (0.34) F10KMT2APOLBMEN1TDP1
SCHEMBL5530436 0.84 F10 (0.34) F10F2NPC1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP claimed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US claimed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO claimed
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP disclosed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US disclosed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069250-A1 Benzamide inhibitors of factor Xa SERPINC1, TFPI, F12 F10 10/4885F2 16/4885P2RX1 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.